Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 06, 2023 11:04am
129 Views
Post# 35383016

RE:crosstalk between senescent cells and CD8 T cell-dependent a

RE:crosstalk between senescent cells and CD8 T cell-dependent aONCY's pelareorep (reovirus) capabiltiy of remodeling an immunosuppressive / hypoxic tumor microenvironment (TME) results in the ability upregulating of turning "cold" tumors into "hot" tumors  through innate and adaptive immune responses to treat a variety of cancers, and overcoming the issue of T-Cell exhaustion through clonal proliferation of T-cell and the prevention of MHC-1 loss through the expanded expression of MHC-1 ligand (Murphy et al., 2019), leading to the increase of CD8+ T-cells, along with dendritic and NK immune cells involved in the "cross priming" in the TME.

Cross priming is a process which dendritic cells activate CD8+ T cells by cross presenting exogenous antigens, and plays a critical role in generating anti-tumor CD8+ T-cell immunity, which is an accomplishment that ONCY's oncolytic virus pelareorep has demonstrated in ONCY's Aware-1, Bracelet-1 and Goblet-1 Phase 2 clinical trials. . 

<< Previous
Bullboard Posts
Next >>